cells that may have remained after previous intensive consolidation. Currently, the prevailing consensus is that maintenance therapy is mandatory in patients with acute lymphoblastic leukemia (ALL), whereas those with acute myeloid leukemia (AML) are
Search Results
Postconsolidation Maintenance and Monitoring in Patients With Acute Promyelocytic Leukemia
Chezi Ganzel, Dan Douer, and Martin S. Tallman
Debate: What Is Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?
Presented by: Mazyar Shadman and Deborah M. Stephens
and cons of chemoimmunotherapy versus ibrutinib,” he said. After FCR, the risk of treatment-related myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) is 5%. However, patients with mutated IGHV have durable long-term remissions from FCR
Myelodysplastic Syndromes
Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H. Joachim Deeg, James M. Foran, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Stephen D. Nimer, Margaret R. O'Donnell, Mark A. Schroeder, Paul J. Shami, Richard M. Stone, James E. Thompson, and Peter Westervelt
for MDS to evolve into acute myeloid leukemia (AML). In the general population, MDS occur in 5 per 100,000 people. However, among individuals older than 70 years, the incidence increases to between 22 and 45 per 100,000 and increases further with age
Blastic Plasmacytoid Dendritic Cell Neoplasm
Akriti Jain and Kendra Sweet
have been recognized to be associated with various myeloid neoplasms, including chronic myelomonocytic leukemia (CMML), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML), and have also been hypothesized to be clonally related to BPDCN
NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
Ruben A. Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Christopher D. Fletcher, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Brandon McMahon, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolaos Papadantonakis, Philip Pancari, Nikolai Podoltsev, Raajit Rampal, Erik Ranheim, Vishnu Reddy, Lindsay A.M. Rein, Bart Scott, David S. Snyder, Brady L. Stein, Moshe Talpaz, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, and Hema Sundar
Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.
Myelodysplastic Syndromes Clinical Practice Guidelines in Oncology
Roswell Park Cancer Institute
The myelodysplastic syndromes (MDS) represent myeloid clonal hemopathies with relatively heterogeneous spectrums of presentation. The major clinical problems in these disorders are morbidities caused by patients' cytopenias and the potential for MDS to evolve into acute myeloid leukemia (AML). Managing MDS is complicated by the generally advanced age of the patients (median ages range from 65–70 years), the attendant non-hematologic comorbidities, and older patients' relative inability to tolerate certain intensive forms of therapy. In addition, when the illness progresses into AML, these patients experience lower response rates to standard therapy than patients with de novo AML.
For the most recent version of the guidelines, please visit NCCN.org
Myelodysplastic Syndromes
The UNMC Eppley Cancer Center at The Nebraska Medical Center
Myelodysplastic syndromes (MDS) represent myeloid clonal hemopathies with relatively heterogeneous spectrums of presentation. The major clinical problems in these disorders are morbidities caused by patients' cytopenias and the potential for MDS to evolve into acute myeloid leukemia (AML). Managing MDS is complicated by the generally advanced age of patients, attendant non-hematologic comorbidities, and older patients' relative inability to tolerate some therapies. In addition, when the illness progresses into AML, these patients experience lower response rates to standard therapy than patients with de novo AML. Important changes from the 2008 version of the guidelines include the addition of lenalidomide as a possible treatment for symptomatically anemic non-del(5q) patients whose anemia does not respond to initial therapy.
For the most recent version of the guidelines, please visit NCCN.org
Highlights of the NCCN Oncology Research Program
Investigator: Sanjay Mohan, MD Condition: Acute myeloid leukemia Institution: Vanderbilt-Ingram Cancer Institute This phase II trial evaluates how well decitabine + cedazuridine (DEC-C) work in combination with venetoclax in treating patients with
CGE22-103: Identifying Patients at Risk for Hereditary Myeloid Malignancy Syndromes Using a Self-Administered Questionnaire as an Initial Screening Tool: A Single Center Experience
Mohammad Faizan Zahid, Courtney Dryden, Ruth Ikpefan, Kelsey Moriarty, Robert H Collins, Madhuri Vusirikala, Yazan F Madanat, and Prapti A Patel
Background : Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) mostly arise from somatic mutations. 4-10% of patients with MDS/AML have an inherited predisposition to bone marrow failure or myeloid malignancy. The increasing use
Highlights of the NCCN Oncology Research Program
Principal Investigator: Sanjay Mohan, MD Condition: Acute myeloid leukemia Institution: Vanderbilt-Ingram Cancer Institute This phase II trial evaluates how well decitabine + cedazuridine (DEC-C) work in combination with venetoclax in treating
